In NSCLC patients with at least 50% of PD‐L1 expression, monotherapy with ICI is likely to result in better overall survival rate, as well as a higher progression‐free survival and overall response rate compared to platinum‐based chemotherapy. This evidence concerns the gene CD274 and non-small cell lung carcinoma.